In recent years, several novel emerging groups of anti-HER2 agents, including antibody-based fragments (Fabs), diabodies, minibodies, nanobodies (Nbs), and affibodies, have been explored for HER2-positive breast cancer imaging and targeted radionuclide therapy.40 This evidence concerns the gene ERBB2 and breast carcinoma.